Rare Nephrology News

Spotlight On

Focal segmental glomerulosclerosis (FSGS)

Focal segmental glomerulosclerosis is scattered mesangial sclerosis that begins in some glomeruli and eventually involves all glomeruli



US Estimated


Europe Estimated

Age of Onset





Autosomal dominant


Autosomal recessive




X-linked dominant


X-linked recessive


Rare View

5 Facts you should know



It is characterized by scar tissue that forms in some of the glomeruli in the kidney



Key signs and symptoms include proteinuria, water retention, and edema



Diagnosis is established by renal biopsy



FSGS occurs more frequently in adults than in children and is most prevalent in adults aged 45 and older



Black Americans are at least four times more likely to get FSGS in comparison with white Americans

Focal segmental glomerulosclerosis (FSGS) is also know as...

Focal segmental glomerulosclerosis (FSGS)

FSGS, focal glomerular sclerosis, focal nodular glomerulosclerosis

What’s your Rare IQ?

Which of these symptoms in most likely to be seen in a patient with FSGS?

Common signs & symptoms

Protein in the urine

Elevated levels of creatinine


Current treatments

At the time this analysis was conducted, there were no current treatments for this disease.

Top Clinical Trials

TitleDescriptionPhasesStatusInterventionsMore Information
Obinutuzumab in Primary FSGSThe purpose of this study is to evaluate the safety and efficacy of Obinutuzumab in inducing complete or partial remission of proteinuria.Phase 2RecruitingDrug: ObinutuzumabClick here for more information
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change DiseaseThe researchers are testing adalimumab, a treatment which blocks tumor necrosis factor (TNF), to see if it changes levels of urine biomarker levels (TIMP1 and MCP1).Phase 2RecruitingDrug: adalimumabClick here for more information
Use of Acthar in Patients With FSGS That Will be Undergoing Renal TransplantationThis study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence.Phase 3RecruitingDrug: ActharClick here for more information
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-TransplantThis is a phase III, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to kidney transplantation can prevent recurrent FSGS in children and adults.Phase 3RecruitingDrug: Rituximab|Procedure: PlasmapheresisClick here for more information
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusions in adult subjects with FSGS.

Phase 2RecruitingDrug: PF-06730512Click here for more information
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change DiseaseThis is a phase 2a study evaluating the safety and tolerability of multiple ascending doses of GFB-887 in patients with diabetic nephropathy (DN), focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change disease (TR-MCD).Phase 2RecruitingDrug: GFB-887|Drug: PlaceboClick here for more information
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular DiseasesTo evaluate the safety, efficacy and tolerability of sparsentan oral suspension and assess changes in proteinuria after once-daily dosing over the 108-week treatment period.Phase 2RecruitingDrug: SparsentanClick here for more information
Atrasentan in Patients With Proteinuric Glomerular DiseasesThe AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.Phase 2RecruitingDrug: AtrasentanClick here for more information

Top Treatments in Research

AgentClass/Mechanism of ActionDevelopment StatusCompanyClinical StudiesMore Information
ObinutuzumabHumanized anti-CD20 monoclonal antibodyPhase 2Mayo ClinicClick here for more informationClick here for more information
adalimumabAdalimumab is a monoclonal antibody to human tumor necrosis factor (TNF) alphaPhase 2University of MichiganClick here for more informationClick here for more information
ActharACTH is an important component of the hypothalamic-pituitary-adrenal axis and is often produced in response to biological stress (along with its precursor corticotropin-releasing hormone from the hypothalamus). Its principal effects are increased production and release of cortisol by the cortex of the adrenal gland.Phase 3University of Colorado, DenverClick here for more informationClick here for more information
Rituximab/PlasmapheresisThe antibody binds to the cell surface protein CD20Phase 3University of MinnesotaClick here for more informationClick here for more information
PF-06730512An Fc fusion protein that targets the ROBO2/SLIT2 pathwayPhase 2PfizerClick here for more informationClick here for more information
GFB-887GFB-887 is a precision-based, podocyte-targeting, small molecule inhibitor of TRPC5, designed specifically to treat individuals with kidney diseases associated with an over-activation of the TRPC5-Rac1 pathwayPhase 2Goldfinch Bio, Inc.Click here for more informationClick here for more information
SparsentanSparsentan, which possesses two clinically validated mechanisms of action in a single molecule, works by selectively blocking the action of two potent vasoconstrictor and mitogenic agents, angiotensin II (AII) and endothelin 1 (ET1), at their respective receptors. Sparsentan is highly selective (10,000-fold) for the AII receptor sub-type 1 and the ET receptor sub-type A. As such, Sparsentan combines the properties of an angiotensin receptor blocker (ARB) and an endothelin receptor antagonist (ERA) in the same molecule.Phase 3Travere Therapeutics, Inc.Click here for more informationClick here for more information
AtrasentanAtrasentan is a selective and potent inhibitor of the endothelin A receptor, or ETA, which has the potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preserve kidney function.Phase 2Chinook Therapeutics U.S., Inc.Click here for more informationClick here for more information